high-efficacy disease-modifying therapymultiple sclerosisMSrelapsing-remitting MS
…was 7.8 years (IQR: 4.9–9.6) and 69.6% of participants received high-efficacy disease-modifying therapy during follow-up. Baseline LVV was a significant predictor of t…